• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Lipid management: tools for getting to the goal.

作者信息

McKenney J M

出版信息

Am J Manag Care. 2001 Aug;7(9 Suppl):S299-306.

PMID:11517816
Abstract

The treatment of hypercholesterolemia in the United States begins with the recognition of elevated low-density lipoprotein cholesterol (LDL-C) as the primary target. An optimal LDL-C level has been defined as < 100 mg/dL. The first step in lowering LDL-C continues to be lifestyle modification, which includes a restriction of saturated fat and cholesterol, increased physical activity, and weight loss, if applicable. Approximately half of all patients with elevated LDL-C levels will ultimately need treatment with a lipid-lowering drug to achieve treatment goals. The preferred drug for first-line treatment in most patients is a statin; a bile acid resin or niacin can be used in patients who cannot tolerate statins or who are not candidates for stain therapy. Combination therapy is an option, with several combinations showing efficacy in lowering LDL-C (statin plus bile acid resin, niacin plus bile acid resin) and in lowering both LDL-C and triglycerides (statin plus fibrate, statin plus niacin, bile acid resin plus niacin). Successful lipid management includes treating to reach the LDL-C goal level, treating to reach the non-high-density lipoprotein cholesterol goal level if applicable, and managing other risk factors for coronary heart disease.

摘要

相似文献

1
Lipid management: tools for getting to the goal.
Am J Manag Care. 2001 Aug;7(9 Suppl):S299-306.
2
Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.高胆固醇血症治疗达标:辛伐他汀联合依折麦布双重抑制胆固醇合成与吸收
Curr Med Res Opin. 2006 Mar;22(3):511-28. doi: 10.1185/030079906X89856.
3
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.在重度高胆固醇血症高危患者中实现脂蛋白目标:依折麦布与阿托伐他汀联合应用的疗效和安全性。
Am Heart J. 2004 Sep;148(3):447-55. doi: 10.1016/j.ahj.2004.03.052.
4
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.近期临床试验对美国国家胆固醇教育计划成人治疗专家组第三次指南的影响。
Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. doi: 10.1161/01.ATV.0000133317.49796.0E.
5
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.近期临床试验对美国国家胆固醇教育计划成人治疗专家组第三次指南的影响。
J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. doi: 10.1016/j.jacc.2004.07.001.
6
Management of dyslipidemia in the high-risk patient.高危患者血脂异常的管理。
Am Heart J. 2002 Dec;144(6 Suppl):S43-50. doi: 10.1067/mhj.2002.130302.
7
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.盐酸考来维仑在高胆固醇血症患者中与他汀类药物联用时对低密度脂蛋白胆固醇和高敏C反应蛋白的影响。
Am J Cardiol. 2006 Apr 15;97(8):1198-205. doi: 10.1016/j.amjcard.2005.11.039. Epub 2006 Mar 3.
8
Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.依折麦布与辛伐他汀联合治疗高危患者与单独使用辛伐他汀治疗以达到美国国家胆固醇教育计划成人治疗组第三次报告的低密度脂蛋白胆固醇目标。
Am J Cardiol. 2004 Jun 15;93(12):1481-6. doi: 10.1016/j.amjcard.2004.02.059.
9
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.在MERCURY I试验中,瑞舒伐他汀与阿托伐他汀、辛伐他汀和普伐他汀在实现胆固醇目标及改善伴有或不伴有代谢综合征的高胆固醇血症患者血脂方面的比较。
Diabetes Obes Metab. 2005 Jul;7(4):430-8. doi: 10.1111/j.1463-1326.2004.00450.x.
10
Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.依折麦布与他汀类药物联合使用治疗男性和女性高胆固醇血症时疗效和安全性的一致性。
J Womens Health (Larchmt). 2004 Dec;13(10):1101-7. doi: 10.1089/jwh.2004.13.1101.

引用本文的文献

1
Faecal bacterial and short-chain fatty acids signature in hypercholesterolemia.高脂血症中的粪便细菌和短链脂肪酸特征。
Sci Rep. 2019 Feb 11;9(1):1772. doi: 10.1038/s41598-019-38874-3.
2
Dual use of amphiphilic macromolecules as cholesterol efflux triggers and inhibitors of macrophage athero-inflammation.两亲性大分子作为胆固醇流出触发因子和巨噬细胞动脉粥样炎症抑制剂的双重用途。
Biomaterials. 2011 Nov;32(32):8319-27. doi: 10.1016/j.biomaterials.2011.07.039. Epub 2011 Aug 3.
3
Controllable inhibition of cellular uptake of oxidized low-density lipoprotein: structure-function relationships for nanoscale amphiphilic polymers.
可控制的氧化型低密度脂蛋白细胞摄取抑制:纳米两亲聚合物的结构-功能关系。
Acta Biomater. 2010 Aug;6(8):3081-91. doi: 10.1016/j.actbio.2010.02.019. Epub 2010 Feb 17.
4
Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study.对于接受他汀类药物单药治疗但未达到低密度脂蛋白胆固醇(LDL-C)目标值的原发性高胆固醇血症患者,每日服用10毫克依折麦布并联合他汀类药物的疗效和耐受性:一项加拿大多中心前瞻性研究——依折麦布附加治疗研究
Can J Cardiol. 2006 Oct;22(12):1035-44. doi: 10.1016/s0828-282x(06)70319-1.
5
Potential cellular receptors involved in hepatitis C virus entry into cells.参与丙型肝炎病毒进入细胞过程的潜在细胞受体。
Lipids Health Dis. 2005 Apr 19;4:9. doi: 10.1186/1476-511X-4-9.
6
Managing dyslipidemia in chronic kidney disease.慢性肾脏病患者血脂异常的管理
J Gen Intern Med. 2004 Oct;19(10):1045-52. doi: 10.1111/j.1525-1497.2004.40049.x.
7
Management of hypercholesterolaemia in postmenopausal women.绝经后女性高胆固醇血症的管理
Drugs Aging. 2002;19(3):169-78. doi: 10.2165/00002512-200219030-00002.